Cogstate secures $25.1M in new sales
- Cogstate executed $25.1 million in net sales contracts during the September quarter.
- Following the announcement, Cogstate shares rose to $3.78.
- Market share gains in mood disorders and expanded channel partnerships propelled contract growth.
Cogstate (ASX:CGS) reported US$25.13 million in executed net sales contracts for the quarter ended Sept. 30, marking a 17% increase over the previous corresponding period.
The quarterly result compares to US$21.4 million recorded in the September 2025 quarter and US$21.9 million in the June 2026 quarter.
The performance was supported by competitive wins in mood disorders, including five Phase 3 trials across bipolar disorder and depression that contributed over 80% of total quarterly contract value.
Contracted revenue reached US$143.7 million as of Sept. 30, 2026.
The company stated that its channel partnership strategy enabled access to programmes that were previously more difficult to win independently.
Following the announcement, the Cogstate share price was up at $3.78.
Cogstate specialises in digital cognitive assessments and data quality management for clinical trial endpoint measurements.
The business continues to combine scientific expertise in central nervous system testing with third-party clinical technology providers.
